Ceritinib gained US Food and Drug Administration approval in 2014 for the treatment of patients with ALK-positive metastatic non-small-cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib [8]. This evidence concerns the gene ALK and non-small cell lung carcinoma.